The Sustainable Development Goals (SDGs) were formally adopted at the United Nations General Assembly in 2015 as universal targets that should be achieved by 2030. Astellas assessed the impact on the SDGs across its entire value chain and identified items for priority action, using the SDG Compass as a reference. We contribute to the attainment of the SDGs through a variety of business activities, mainly those related to health and welfare aligned with “Goal 3: Good Health and Well-Being.”
Goal 3: Good Health and Well-Being
Astellas is tackling the SDGs with a focus on Goal 3, which has the strongest affinity to its business philosophy to “contribute toward improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.” Health is not just a healthcare issue, because losing health could lead to restricting opportunities for education or employment and be the cause of poverty in cases. In light of this, attaining Goal 3 will also contribute to achieving the other SDGs.
Improving Access to Health in Four Areas
Astellas is addressing Goal 3 of the SDGs by improving Access to Health. There are many people with insufficient access to the healthcare they need due to the lack of available treatments, poverty, challenges in healthcare systems and limited healthcare information. We recognize this problem as an Access to Health issue, and have identified four areas where we are working to address such issues by making full use of the strengths and technology that we have. The four areas are (1) Creating innovation, (2) Enhancing availability, (3) Strengthening healthcare systems, and (4) Improving health literacy. In doing so, we will make maximum use of our partnerships in the manner of Goal 17 of the SDGs.
In creating innovation, Astellas is working to create innovative medicines and medical solutions in disease areas with low treatment satisfaction and delivering them to patients around the world. Moreover, Astellas has been conducting collaborative research with partners for the purpose of creating lead compounds for tuberculosis, malaria, and neglected tropical diseases (Leishmaniasis and Chagas disease). Also Astellas has been working to develop a pediatric formulation of praziquantel tablets for the treatment of schistosomiasis with the consortium members.
To help enhance availability, we have established programs to assist patients facing severe financial constraints with the cost of pharmaceutical products. We also support patients by not filing or enforcing patents in countries facing significant economic challenges.
As part of strengthening healthcare systems and improving health literacy, Astellas has participated in the Access Accelerated global partnership. This initiative aims to contribute to achieving the SDG of reducing premature mortality from non-communicable diseases by one-third by 2030.
In other SDG-related initiatives, Astellas has supported Kenya’s ACTION ON FISTULA program, contributing to improving the environment encompassing Kenya’s fistula patients. Furthermore, we have also donated ambulances and wheelchair transport vehicles and moved forward in activities supporting patient associations.
Moreover, Astellas is working on resolving issues related to Access to Health in countries where Astellas does not have a commercial presence through the Astellas Global Health Foundation (AGHF).
Other Initiatives for SDGs
|SDGs||Examples of Astellas’ initiatives|